Trial Profile
Phase Ib/II clinical trial of ruxolitinib in combination with nilotinib and prednisona for myelofibrosis: RuNiC study
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Feb 2022
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Prednisone (Primary) ; Ruxolitinib (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions
- Acronyms RuNiC
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 18 Jul 2020 Status changed from recruiting to discontinued.
- 18 Aug 2017 New trial record